February business climate 3.5% riskier

Israel's business climate was 3.5% riskier in February, with 46,400 companies in danger of closing, up from 44,800 in January, Business Data Israel said Monday.

By DANIEL KENNEMER
March 14, 2006 07:55

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Israel's business climate was 3.5 percent riskier in February, with 46,400 companies in danger of closing, up from 44,800 in January, Business Data Israel said Monday. Roughly 14.5% of businesses in Israel were at a particularly high risk of closure and 15.3% were at above average risk, up from 14% and 14.9%, respectively, in January, while the proportion of those at medium risk slipped to 62% from 62.9%. BDI's risk index rose 1% to 5.98 from 5.92 in January, the firm said, noting that the index was still much better than its February 2005 level of 6.09. Holidays are expected to boost the state of Israel's businesses in April and May, BDI said.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS